文献速递肿瘤 PET/CT核素与放射性配体治疗

应用新型PSMA-PET与PSA联合模型提高PI-RADS≤3男性中临床显著前列腺癌的诊断准确性并避免不必要活检

Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-10-15

本研究回顾性纳入151例临床怀疑前列腺癌且MRI PI-RADS≤3的男性,均行[68Ga]Ga-PSMA PET/CT及融合引导活检。由PRIMARY-score、SUVmax和血清fPSA/tPSA构建的诊断模型AUC达0.906,显著高于基于PRIMARY-score或SUVmax的策略(P<0.05),并明显优于常规基于PSA密度的策略(P<0.001);采用21.6%阈值理论上可避免78%的不必要活检,仅遗漏7.8%的临床显著前列腺癌。

要点

  • 在PI-RADS≤3男性中,PRIMARY-score、SUVmax和常规PSMA-PET评估检出临床显著前列腺癌的AUC分别为0.796、0.851和0.806。
  • 由PRIMARY-score、SUVmax和fPSA/tPSA构建的模型AUC为0.906,显著高于PRIMARY-score或SUVmax策略(P<0.05),并明显优于常规PSA密度策略(P<0.001)。
  • 采用21.6%阈值,理论上可避免78%的不必要活检,仅遗漏7.8%的临床显著前列腺癌。

核心结论

  • 由PSMA-PET衍生的PRIMARY-score和SUVmax联合血清fPSA/tPSA构建的新型诊断模型已开发并验证,可能辅助临床决策,其诊断准确性优于单个常规指标。
  • 该模型在PI-RADS≤3 MRI男性中具有减少不必要活检的较大潜力,但需进一步前瞻性和外部评估。

研究设计与样本

  • 本研究为回顾性研究,纳入151例临床怀疑前列腺癌且MRI PI-RADS≤3的男性。
  • 所有患者均接受[68Ga]Ga-PSMA PET/CT扫描以及超声/MRI/PET融合引导活检。
  • 临床显著前列腺癌定义为Grade Group≥2。
  • 评估PSMA-PET扫描的PRIMARY-score,并构建包含PSMA-PET和PSA衍生参数的诊断模型。
  • 采用五折交叉验证进行内部验证,迭代1000次。

主要发现

  • 在PI-RADS≤3队列中,检出临床显著前列腺癌的AUC:PRIMARY-score为0.796(95%CI,0.738-0.853),SUVmax为0.851(95%CI,0.783-0.918),常规临床PSMA-PET评估为0.806(95%CI,0.742-0.870)。
  • 包含PRIMARY-score、SUVmax和血清fPSA/tPSA的诊断模型AUC为0.906(95%CI,0.851-0.961),显著高于基于PRIMARY-score或SUVmax的策略(P<0.05),并明显优于常规基于PSA密度的策略(P<0.001)。
  • 五折交叉验证(迭代1000次)的平均AUC为0.878(95%CI,0.820-0.954)。
  • 理论上,采用21.6%的阈值,该模型在本队列中可避免78%的不必要活检,仅遗漏7.8%的临床显著前列腺癌病例。

关键数值与推荐

  • 临床显著前列腺癌定义为Grade Group≥2。
  • 诊断模型包含PRIMARY-score、SUVmax和血清fPSA/tPSA。
  • 模型AUC为0.906(95%CI,0.851-0.961),五折交叉验证平均AUC为0.878(95%CI,0.820-0.954)。
  • 采用21.6%阈值时,理论上可避免78%的不必要活检,遗漏7.8%的临床显著前列腺癌。

临床怎么用

  • 作者认为,该整合模型可能辅助临床决策,在PI-RADS≤3 MRI男性中减少不必要活检。
  • 作者指出,该模型需进一步前瞻性和外部评估。

局限性

  • 原文报告该研究为回顾性研究。
  • 原文指出需进一步前瞻性和外部评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The diagnostic evaluation of men with suspected prostate cancer (PCa) yet inconclusive MRI (PI-RADS ≤ 3) presents a common clinical challenge. [68Ga]Ga-labelled prostate-specific membrane antigen ([68Ga]Ga-PSMA) positron emission tomography/computed tomography (PET/CT) has shown promise in identifying clinically significant PCa (csPCa). We aim to establish a diagnostic model incorporating PSMA-PET to enhance the diagnostic process of csPCa in PI-RADS ≤ 3 men. MATERIALS AND METHODS: This study retrospective included 151 men with clinical suspicion of PCa and PI-RADS ≤ 3 MRI. All men underwent [68Ga]Ga-PSMA PET/CT scans and ultrasound/MRI/PET fusion-guided biopsies. csPCa was defined as Grade Group ≥ 2. PRIMARY-scores from PSMA-PET scans were evaluated. A diagnostic model incorporating PSMA-PET and prostate-specific antigen (PSA)-derived parameters was developed. The discriminative performance and clinical utility were compared with conventional methods. Internal validation was conducted using a fivefold cross-validation with 1000 iterations. RESULTS: In this PI-RADS ≤ 3 cohort, areas-under-the-curve (AUCs) for detecting csPCa were 0.796 (95%CI, 0.738-0.853), 0.851 (95%CI, 0.783-0.918) and 0.806 (95%CI, 0.742-0.870) for PRIMARY-score, SUVmax and routine clinical PSMA-PET assessment, respectively. The diagnostic model comprising PRIMARY-score, SUVmax and serum free PSA/total PSA (fPSA/tPSA) achieved a significantly higher AUC of 0.906 (95%CI, 0.851-0.961) compared to strategies based on PRIMARY-score or SUVmax (P < 0.05) and markedly superior to conventional strategies typically based on PSA density (P < 0.001). The average fivefold cross-validated AUC with 1000 iterations was 0.878 (95%CI, 0.820-0.954). Theoretically, using a threshold of 21.6%, the model could have prevented 78% of unnecessary biopsies while missing only 7.8% of csPCa cases in this cohort. CONCLUSIONS: A novel diagnostic model incorporating PSMA-PET derived metrics-PRIMARY-score and SUVmax-along with serum fPSA/tPSA, has been developed and validated. The integrated model may assist clinical decision-making with enhanced diagnostic accuracy over the individual conventional metrics. It has great potential to reduce unnecessary biopsies for men with PI-RADS ≤ 3 MRI results and warrants further prospective and external evaluations.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li Y, Li J, Yang J, et al. Using a novel PSMA-PET and PSA-based model to enhance the diagnostic accuracy for clinically significant prostate cancer and avoid unnecessary biopsy in men with PI-RADS ≤ 3 MRI. Eur J Nucl Med Mol Imaging. 2024. PMID: 39404788. doi:10.1007/s00259-024-06949-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。